Sio Gene Therapies Inc
F:6YY

Watchlist Manager
Sio Gene Therapies Inc Logo
Sio Gene Therapies Inc
F:6YY
Watchlist
Price: 0.3265 EUR Market Closed
Market Cap: €24.2m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
€0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Sio Gene Therapies Inc
F:6YY
24.2m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Sio Gene Therapies Inc
Glance View

Market Cap
24.2m EUR
Industry
Biotechnology

Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company is headquartered in New York City, New York and currently employs 42 full-time employees. The company went IPO on 2015-06-11. The firm is focused on developing gene therapies for neurodegenerative diseases. The firm is developing a pipeline of product candidates for the treatment of these debilitating diseases, including GM1 gangliosidosis, GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases, and Parkinson's disease. The firm is under three clinical-stage programs, AXO-AAV-GM1, AXO-AAV-GM2 and AXO-Lenti-PD. The AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis. The program utilizes an adeno-associated virus (AAV) vector to deliver a functional copy of the GLB1 gene. The AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases. The AXO-AAV-GM2 program utilizes dual AAV vectors to deliver functional copies of both the HEXA gene and the HEXB gene. The AXO-Lenti-PD program for the treatment of Parkinson's disease, comprised of the ProSavin Phase 0.5 study.

6YY Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top